Skip to main content
Download PDF

Prevalence and risk factors of human papilloma virus infection among women living with HIV, Egypt, a cross sectional study

BMC Public Health volume 24, Article number: 1821 (2024) Cite this article

Abstract

Background

HPV is considered the most common sexually transmitted infection. It is responsible of 70% of cervical cancers worldwide. HIV infection is associated with increased rates of HPV infection. Women Living With HIV (WLWH) are 6 times at greater risk of developing cervical cancer. The current study aimed to estimate prevalence and identify genotypes of HPV infection among WLWH in Egypt compared to women with negative HIV status and determine associated risk factors.

Methods

The study conducted among 251 WLWH and 268 women with negative HIV status enrolled from gynecological clinics in primary health care centers from nine Egyptian governorates. Data was collected from participants using a structured interview questionnaire and cervical samples were collected for HPV DNA detection and genotyping.

Results

The overall prevalence of HPV infection was 13.5%, 3.4% among women with HIV negative status and 24.4% among WLWH. HR-HPVs other than genotype 16 and 18 were isolated from 71% of infected women. Woman’s age, age at first marriage, number of lifetime marriages and drug addiction are significant predictors for HPV infection (odds 0.96, 0.91, 2.06, 2.01 respectively).

Conclusion

HPV infection is more prevalent among WLWH. Infection with HR-HPV other than genotype 16 and 18 was the most prevalent among infected women in both groups. Young age, early life sexual activity, having more than one sexual partner during the life time, and drug addiction are independent predictors for HPV infection. Having a husband who has had other sexual partners is significantly associated with infection.

Peer Review reports

Background

Cervical cancer is considered the 4th most common cancer in women. The HPV (Human Papilloma Virus) information center in 2023 estimated the worldwide incidence rate of cervical cancer among women in the reproductive age to be 13.1 per 100,000 women [1]. In 2020, the estimated number of women diagnosed with cervical cancer globally was 604,000 women with estimated 342,000 deaths from the disease [2]. In Egypt, the World Health Organization (WHO) estimated the crude incidence rate of cervical cancer in women to be 2.6/ 100,000 women in 2020 with a total 620 fatalities from the disease in 2019 [3].

Early in 20th century a relationship was suspected between cervical cancer and sexual behavior which then confirmed in 1960s. In 1980s, HPV was detected in cervical cancer cells. This finding was the starting point for further research which confirmed the presence of a consistent association between HPV and cervical cancer where nearly all cases of cervical cancer are found to be due to chronic HPV infection [4,5,6].

HPV is considered the most common sexually transmitted viral infection. There are more than 170 HPV genotypes among them 15 types are recognized as high risk (HR HPV) or cancer-causing genital HPVs. HPV type 16 and 18 are considered the most prevalent types detected in HPV associated cancers. They were found to be responsible of about 70% of cervical cancers worldwide [7, 8].

HIV is associated with increased rates of HPV infection. In addition of being both sexually transmitted infection, HIV positive status facilitates HPV persistence after acquisition of infection and modulates the expression of HPV E6 and E7 genes which are responsible of oncogenic transformation. It was found that women living with HIV(WLWH) are 6 times at greater risk of developing cervical cancer [9, 10].

The Middle East and North Africa region (MENA) involves many countries and territories which are markedly varied regarding their demographic trends, dynamics and gross national income. Urban and young population is dominating in the region with more than half of the population is under the age of 25. Islam is the dominating religion in the region. Egypt is considered one of the region’s middle-income countries [11, 12]. Although the Middle East and North Africa is the region of the lowest HIV burden in the world with 190,000 People living with HIV (PLWH) in 2022, the number of new HIV infections increased by 33% from year 2010 to 2021 and reach 61% increase by year 2023 making the HIV epidemic in the region on the rise. This increase is driven primarily by transmission among population with high-risk behaviors and their sexual partners who estimated to have accounted for 85% of those new infections. These numbers represent only people who presented themselves for testing as the region is still facing the problem of underdiagnosis and inefficient testing. In year 2022, it was found that only 67% of PLWH knew their HIV status. In Egypt, it is estimated that there was 34,000 PLWH in 2022, among them there were 5700 WLWH [13]. HPV Vaccine is not yet introduced in the Egyptian national immunization program however it is introduced in the private sector since 2009 to those who desire and can afford the cost. Moreover, till date, there is no Egyptian national cervical cancer screening program [3]. Focusing on the prevention and treatment of HIV and cervical cancer, integration of services will maximize the benefits [14].

In 2020, WHO launched the Global strategy to accelerate the elimination of cervical cancer as a public health problem. The strategy has three main global targets for 2030 including “90% of girls are fully vaccinated with HPV vaccine by age 15 years, 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age, 90% of women identified with cervical disease receive treatment”. The currently available HPV vaccines include bivalent vaccines (HPV 16 & 18), quadrivalent vaccine where genotypes 6 and 11 added and the 9-valent vaccine including, in addition, genotypes 31, 33, 45, 52 and 58. Based on the Global strategy targets, WHO updated its guidelines with inclusion of 16 recommendations and good practice statements for WLWH. The key features of these recommendations include HPV DNA detection for primary screening starting at the age of 25 years with regular screening every 3 to 5 years; partial genotyping, colposcopy or cytology should be carried out to triage women who tested positive” triage a second test for positive cases”; and treatment of detected precancerous lesions and histologically confirmed adenocarcinoma in situ through large-loop excision of the transformation zone or cold knife conization [14].

On preparation for launching of the Egyptian presidential initiative for early detection of cancers including cancer cervix, this study was conducted aiming to provide an estimate for HPV prevalence - as the main cause for occurrence of cancer cervix- among women living with HIV compared to women with negative HIV status in Egypt, identify the types of HPVs isolated from infected women and determine risk factors associated with infection.

Methods

A cross sectional study was conducted among a convenient sample of WLWH and women with negative HIV status who were recruited from nine Egyptian governorates representing the different geographical regions, cultures, behaviours, norms and traditions in Egypt namely Cairo, Giza, Alexandria, Al-Qalyubia, Dakahlia, Gharbia, Sharkia, Fayoum and AL-Minia.

By using Epi Info software for sample size calculation and based on 48% estimated prevalence of HPV infection among WLWH and 28% among HIV negative women [15], with equal allocation of women in both groups, the minimum sample size required in each group was 65 women.

Based on the calculated sample size, a percentage for the number of women recruited from each governorate was allocated so as to respect weighing as per the number of Women living with HIV registered in each governorate. Data was collected at the gynaecological clinics in primary health care centres at these nine governorates. Target population included women aged 18 to 50 years old attending those clinics and WLWH who were referred to those clinics from the HIV care centres during the four months period of the field work (from March to June 2023) and agreed to provide a sample for HPV testing. Exclusion criteria included having abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed, history of hysterectomy, known diagnosis of immunosuppression or patient on immunosuppressive medications, pregnant women, having received one or more doses of HPV vaccine, and having any gynaecological cancer.

A capacity building program was designed and implemented to train all physicians and nurses who are responsible for providing care at the study settings on the designed data collection tool and methodology of cervical sample collection for HPV DNA detection. Women who attended the clinics during the period of the field work; fulfil the inclusion and exclusion criteria and voluntarily accepted participation in the study; were exposed to pregnancy testing to confirm being non pregnant and HIV testing for the control group to confirm being negative before enrolment in the study.

All participants were interviewed by the clinic physician using the designed structured interview questionnaire to collect data regarding their sociodemographic characteristics, reproductive data and risk factors for sexually transmitted infections. Women were instructed at least 48 h before taking the cervical smear sample to void, cleaning the genital area by using vaginal douches and using the condom if there was any sexual practice.

Cervical smear samples were collected using a brush inserted into the cervix, pushed gently and rotated five times in a clockwise direction, rinsed as quickly as possible ten times into the solution vial then swirled vigorously and discarded. The cap was tightened so that the torque line on the cap passes the torque line on the vial and stored at room temperature. HPV DNA detection was carried out in the central laboratories affiliated to the Egyptian Ministry of Health. The type of the HPV test used was HPV PCR pap smear test (Qualitative nucleic acid test for use on the cobas®ฏ 6800/8800 Systems For in vitro diagnostic use). Intended use Cobas®ฏ HPV for use on the Cobas®ฏ 6800/8800 Systems (cobas®ฏ HPV) is a qualitative in-vitro test for the detection of Human Papillomavirus in clinician-collected cervical specimens using an endocervical brush/spatula or broom and placed in the ThinPrep®ฏ Pap Test™ฏ PreservCyt®ฏ Solution. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. IT detects HPV16 on separate channel, HPV18 on separate channel, and other high-risk HPV mentioned above all on one channel. Data was coded then entered and analysed using IBM SPSS statistics version 20. Categorical variables were presented as number and percentage. For quantitative variables, minimum, maximum, mean and standard deviation were used. Comparisons of studied variables between both study groups (WLWH and control group) were carried out, then according to results of HPV PCR pap smear testing, the studied women were further divided into HPV positive and negative groups. Comparisons between groups were carried out using Chi Square test for categorical variables. If one or more cells in the table has an expected count less than 5Fisher’s Exact test was used for 2 × 2 tables and Monte Carlo test for other contingency tables. For normally distributed quantitative variables, student t test was used while Mann-Whitney U test was used for abnormally distributed variables. Multiple variate logistic regression analysis was used to assess the independent predictors of HPV infection. Chi square test was used to asses significance of the model and odds ratio was used as a measure of risk. All results were interpreted at 5% level of significance.

Results

The study included 519 women, 251 women had laboratory confirmed HIV infection and 268 women with negative HIV status. The study sample were collected from nine governorates representing the main characteristics of different Egyptian governorates as presented in Table 1. The sociodemographic characteristics of studied women are presented in Table 2.

Table 1 Distribution of studied women based on their HIV status and residence
Full size table
Table 2 Distribution of studied women based on their HIV status and sociodemographic characteristics
Full size table

HPV infection screening test showed valid laboratory results for 246 WLWH (5 cases had invalid lab results) and for 264 women in the control group (4 women had invalid lab results). The overall prevalence of high-risk HPV infection among studied women was 13.5% (n = 69). The estimated prevalence of high-risk HPV infection among studied WLWH was 24.4% (n = 60) compared to only 3.4% (n = 9) among the control group and this difference is statistically significant, (Chi square test X2 = 47.961, P˂0.001). Table 3 shows the genotypes of HPVs isolated from positive samples.

Table 3 Distribution of HPV infected women based on type of isolated HPVs
Full size table

On studying the characteristics of women with and without HPV infection, it was revealed that the mean age of HPV infected women (33.43 ± 6.38) was less than the age of women with negative HPV test result (35.35 ± 7.59) and the difference is statistically significant (p = 0.04). Moreover, women with HPV infection had significantly lower age of marriage and greater number of marriages compared to women with negative HPV test results (p = 0.001 & ˂0.001 respectively). There is no statistically significant difference between both studied groups regarding residence, education, years of marriage, history of abortion and use of Intrauterine Device (IUD). (Table 4)

Table 4 Distribution of studied women based on their sociodemographic & reproductive characteristics and laboratory results of HPV screening
Full size table

Studying the risky behaviors that are associated with sexually transmitted diseases, it was found that husband’s sexual relation with other women and women or husband drug addiction have statistically significant association with HPV infection (p˂0.001, 0.002 respectively). (Table 5)

Table 5 Distribution of studied women based on their laboratory results of HPV screening and risk factors for sexually transmitted infections
Full size table

On multiple logistic regression analysis, women’s age, age at first marriage, number of marriages and women and/or husband drug addiction were significant predictors of HPV infection. Table 6 shows that every one-year increase in woman’s age, women are 4% less likely to acquire HPV infection. Every one-year increase in the age at first marriage, women are 9% less likely to acquire HPV infection. Every one unit increase in the number of marriages (reflecting lifetime sexual partners and sexual activity), the odds of HPV positive infection status will increase by 2.069 (the risk of acquiring HPV infection increases by 207%). Being a drug addict or having a husband who is drug addict, will increase the odds of HPV positive infection status by 2.01 (the risk of acquiring infection increases by 201%).

Table 6 Multiple logistic regression analysis of independent predictors of HPV infection
Full size table

Discussion

Sexually active women and men are found to be infected at least once with HPV during their life time making HPV infection the most common sexually transmitted infection worldwide. Although HPV infection is frequently not associated with any pathologies, it is considered the primary cause of female cancers. It is isolated from up to 90% of cervical cancers making it a public health priority for surveillance and monitoring [16, 17].

Regarding the prevalence of HPV infections, Asia and Africa have the highest prevalence among the world continents. Within continent, prevalence of infections is higher in developing compared to developed regions [18]. The current study which is carried out among women from nine governorates representing the different regions of Egypt regarding geographical; social and cultural characteristics; the overall estimated prevalence of infection was 13.5% regardless of the HIV status of studied women. Previous studies carried out in Egypt from year 2006 to 2018 showed a varied prevalence ranging from 10.3% up to 23.1% [19,20,21]. The differences in estimated prevalence between these studies could be attributed to the characteristics of studied women where studies with higher prevalences [19, 21] were conducted among women enrolled from Cairo which is the capital city while the lowest was from a multicenter study [20] conducted among women enrolled from tertiary care hospitals with wide catchment areas. According to biological and behavioral surveillance data in Egypt, risky behaviors are concentrated in Cairo and Alexandria -which are the biggest Egyptian cities- and reflected on the concentrated number of HIV cases among injecting drug users and men who have sex with men in these cities [22].

With focus on the HPV co-infection with HIV, the present study showed a significantly higher prevalence of infection among HIV positive (24.4%) compared to HIV negative women (3.4%). This is similar to results of studies conducted in many other countries worldwide and attributed to the reduced clearance rate and increased persistence of HPV infection in HIV positive women [9, 23,24,25].

Infection with HR-HPVs other than HPV 16 and 18 represents the majority of isolates among both studied groups (71%) followed by mixed infections (17.3%). Solitary infection with HPV16 or 18 represents only around one tenth of infections (11.6%) and was more frequent among women with HIV negative status. This is similar to results reported from other studies conducted in other regions [23, 26]. This finding was expected as HPVs share the same mode of transmission. Also, generated HIV immune responses during seroconversion and associated immunosuppression favor low pathogen clearance, reactivation of HPV latent stage infections and persistence of multiple types of HPVs. Moreover, non-HPV-16 genotypes; which are less efficient at evading the immune system; use the advantage given by HIV associated state of immunosuppression resulting in decrease clearance rate and increased persistence of these infections [27]. Also, it should be taken into consideration that this difference may be attributed to the gathering of HR-HPV other than HPV 16 and 18 in one category based on the used laboratory technique. So, further working on estimating the actual prevalence of individual HR-HPV to identify the most circulating types is recommended with inclusion of more HR-HPV genotypes in the produced HPV vaccines according to these results.

As age is an important determinant in the risk of acquiring HPV infection, the present study revealed that the mean age of HPV positive women is significantly lower than HPV negative women. This finding is on agreement with the fact that HPV infection is most common among sexually active young women with marked decline in prevalence after the age of 30 years [28].

Sexual activity is an important risk for acquiring HPV infection. Sexual activity at an early age, had multiple sexual partners at any time in life and having a partner who has had multiple sexual partners increase the risk of HPV infection [28]. These explain the significant association found between HPV infection and early age of marriage, multiple marriages which reflects the number of lifetime sexual partners and activity and having a husband who has had other sexual partners.

Mechanical disruption of the stratified squamous epithelium of the cervix caused by abortions and insertion of IUDs was found to facilitate HPV virus access to basal cells [29]. But the results of the current study showed insignificant association between history of abortion or use of IUDs and HPV infection and this could be attributed to the small sample size studied in these categories.

The significant association between drug addiction and HPV infection revealed in the current study and other studies is attributed to the high-risk sexual behavior encountered among drug addicts which makes it a common factor associated with both HIV and HPV infection.

Multiple logistic regression analysis revealed that variables related to sexual behavior are the main independent predictors of HPV infection including young age, early age of sexual activity reflected by the early age of marriage, having more than one lifetime sexual partner reflected by multiple marriages and lastly drug addiction which commonly associated with high-risk sexual behaviors.

Conclusion

HPV infection is significantly more prevalent among women living with HIV. Infection with HR-HPVs other than genotype 16 and 18 is the most prevalent among Egyptian women both WLWH and women with HIV negative status. Early marriage, having more than one lifetime sexual partner reflecting high sexual activity and increased exposure risk, having a husband who has had other sexual partners are associated with increased women’s risk of acquiring HPV infection. Drug addiction; due to the associated high risk sexual behavior; is found to be a significant risk factor for HPV infection.

Recommendation

Future research work is recommended to estimate the actual prevalence of individual HR-HPVs and consider results in including more HR-HPV genotypes in the HPV vaccine. Although the low estimated prevalence of HPV infection among Egyptian women with HIV negative status, discussions on the introduction of HPV vaccination in the national immunization program for young girls and boys is recommended in order to prevent infection associated cancers and mortality which have a dramatic sequalae on the social life. Integration of HPV screening and early detection of cervical cancers with HIV services will target the population of the highest risk in a cost-effective manner with maximization of benefits. Drug addiction prevention and control programs should be a public health priority as it will have an indirect effect in prevention of sexually transmitted infections including HIV and HPV.

Data availability

The data that support the findings of this study are available from [Egyptian Ministry of Health & Population] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [Egyptian Ministry of Health & Population].

Abbreviations

HIV:

Human Immunodeficiency Virus

HPV:

Human Papilloma Virus

HR-HPV:

High risk Human Papilloma virus

IUDs:

Intrauterine devices

MENA:

Middle East and North Africa

PCR:

Polymerase Chain Reaction

WHO:

World Health Organization

WLWH:

Women living with HIV

References

  1. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé, S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 10 March 2023. [https://hpvcentre.net/statistics/reports/XWX.pdf].

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  3. World Health Organization. Cervical cancer Egypt 2021, Country profile. [https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-cancer-egy-2021-country-profile-en.pdf?].

  4. Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. J Natl Cancer Inst. 1995;87:779–80.

    Article  CAS  PubMed  Google Scholar 

  5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.

    Article  CAS  PubMed  Google Scholar 

  6. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(Suppl 10):K1–16.

    Article  PubMed  Google Scholar 

  8. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35.

    Article  CAS  PubMed  Google Scholar 

  9. Brickman C, Palefsky JM. Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep. 2015;12:6–15.

    Article  PubMed  Google Scholar 

  10. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health; 2020.

  11. Mendonca VDM, van Diesen A, Beise J, Lee S, Lian B, Mshvidobadze A, et al. MENA Generation 2030. Amman: United Nations Children’s Fund (UNICEF) Regional Office for the Middle East and North Africa; 2019.

    Google Scholar 

  12. Pew Research Center. The Future of World Religions: Population Growth Projections, 2010–2050. 2015. [https://www.pewresearch.org/religion/2015/04/02/middle-east-north-africa/].

  13. UNAIDS. UNAIDS Global Report. 2023. Middle East and North Africa Region. [https://thepath.unaids.org/wp-content/themes/unaids2023/assets/files/regional_fs_east_north_africa.pdf].

  14. World Health Organization. New WHO recommendation on screening and treatment to prevent cervical cancers among women living with HIV: policy brief 2012. [https://www.who.int/publications/i/item/9789240030961].

  15. Tartaglia E, Falasca K, Vecchiet J, Sabusco GP, Picciano G, Di Marco R, et al. Prevalence of HPV infection among HIV-positive and HIV-negative women in Central/Eastern Italy: strategies of prevention. Oncol Lett. 2017;14(6):7629–35. https://doi.org/10.3892/ol.2017.7140. Epub 2017 Oct 5. PMID: 29344211; PMCID: PMC5755221.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Trans Dis. 2014;41:660–4. https://doi.org/10.1097/OLQ.0000000000000193.

    Article  Google Scholar 

  17. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, Jin T. Epidemiology and Burden of Human Papillomavirus and Related diseases, Molecular Pathogenesis, and vaccine evaluation. Front Public Health. 2021;8:552028. https://doi.org/10.3389/fpubh.2020.552028.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K. Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstetr. 2012;285:771–7. https://doi.org/10.1007/s00404-011-2155-814.

    Article  Google Scholar 

  19. Abdel-Aziz MT, et al. Screening for human papillomavirus (HPV) in Egyptian women by the second-generation hybrid capture (HC II) test. Med Sci Monit. 2006;12:43–9.

    Google Scholar 

  20. Shaltout MF, et al. Prevalence and type distribution of human papillomavirus among women older than 18 years in Egypt: a multicenter, observational study. Int J Infect Dis. 2014;29:226–31.

    Article  PubMed  Google Scholar 

  21. Sahar A, Ibrahim SA, Abdel-Salam MI, Amer, Abeer A, El-Sayed RA, Hassan. Prevalence of human papilloma virus (HPV) and type distribution of genotypes (6, 11, 16 and 18) among Egyptian women. Egypt J Med Microbiol. 2020;29(4):45–50. https://doi.org/10.51429/EJMM29406.

    Article  Google Scholar 

  22. Ministry of Health & Population, National AIDS Program Egypt. Biological & Behavioral surveillance survey 2010. [https://www.fhi360.org/wp-content/uploads/drupal/documents/BBSS%202010_0.pdf].

  23. Camargo M, Del Río-Ospina L, Soto-De León SC, Sánchez R, Pineda-Peña AC, Sussmann O, Patarroyo ME, Patarroyo MA. Association of HIV status with infection by multiple HPV types. Trop Med Int Health. 2018; 23(11):1259-68. https://doi.org/10.1111/tmi.13142. Epub 2018 Sep 10. PMID: 30133078.

  24. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795–808. https://doi.org/10.1097/QAD.0000000000001765. PMID: 29369827; PMCID: PMC5854529.

    Article  PubMed  Google Scholar 

  25. Taku O, Businge CB, Mdaka ML, Phohlo K, Basera W, Garcia-Jardon M, Meiring TL, Gyllensten U, Williamson AL, Mbulawa ZZA. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa. Int J Infect Dis. 2020;95:176–82. Epub 2020 Feb 27. PMID: 32114194.

    Article  PubMed  Google Scholar 

  26. Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papilloma virus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30(Suppl 5):F168–74. https://doi.org/10.1016/j.vaccine.2012.06.045.

    Article  CAS  PubMed  Google Scholar 

  27. Maranga IO, Hampson L, Oliver AW, He X, Gichangi P, Rana F, Opiyo A, Hampson IN. HIV infection alters the spectrum of HPV subtypes found in cervical smears and carcinomas from Kenyan women. Open Virol J. 2013;7:19–27. https://doi.org/10.2174/1874357901307010019. Epub 2013 Feb 25. PMID: 23494633; PMCID: PMC3594704.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Okunade KS. Human Papilloma virus and cervical cancer. J Ostet Gynaecol. 2020;40(5):602–8. https://doi.org/10.1080/01443615.2019.1634030.

    Article  CAS  Google Scholar 

  29. Camargo M, Del Río-Ospina L, Soto-De León SC, Sánchez R, Pineda-Peña AC, Sussmann O, et al. Association of HIV status with infection by multiple HPV types. Trop Med Int Health. 2018;111259–68. https://doi.org/10.1111/tmi.13142. Epub 2018 Sep 10. PMID: 30133078.

Download references

Funding

This work is implemented by Egyptian National AIDS Program/ Ministry of Health and Population and supported by UNAIDS (SRH project funded by Embassy of the Kingdom of Netherland).

Author information

Authors and Affiliations

  1. Faculty of Medicine, (Public Health Department), Alexandria University, Alexandria, Egypt

    Mona Ashry

  2. Arab Academy for Science, Technology & Maritime Transport, College of Medicine, Alamein City, Egypt

    Mona Ashry

  3. Central Public Health Laboratory, Ministry of Health & Population, Cairo, Egypt

    Shaimaa Shawky

  4. National AIDS Program, Cairo, Egypt

    Zeinab Mounir & Heba Elsayed

  5. Mother and Child Health Directorate, Ministry of Health & Population, Cairo, Egypt

    Fawzy Fathy

  6. UNAIDS Country Director, Cairo, Egypt

    Walid Kamal

  7. Minister Assistant for Public Health Initiatives and Projects, Ministry of Health & Population, Cairo, Egypt

    Mohamed Hassany

  8. National Hepatology & Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt

    Mohamed Hassany

Authors
  1. Mona Ashry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaimaa Shawky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeinab Mounir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fawzy Fathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heba Elsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walid Kamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohamed Hassany
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

“MA review of study methodology, data analysis & interpretation, and writing the manuscript. SS performed the laboratory work and interpret results. ZM & FF training of data collectors and contribute in writing the manuscript. HE, WK & MH originated the research idea and methodology. MH also supervised all research conduction steps. All authors read and approved the final manuscript.”

Corresponding author

Correspondence to Mona Ashry.

Ethics declarations

Ethical approval

Approval was obtained from the Research Ethics Committee at Ministry of Health before conduction of the study. All participants were informed of the purpose and methodology of the study and a written informed consent was obtained before enrollment. Women tested positive was confidentially notified of this result by the study team and linked to treatment and care services based on the national guidelines and according to the recent HPV treatment recommendations.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ashry, M., Shawky, S., Mounir, Z. et al. Prevalence and risk factors of human papilloma virus infection among women living with HIV, Egypt, a cross sectional study. BMC Public Health 24, 1821 (2024). https://doi.org/10.1186/s12889-024-19240-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12889-024-19240-z

Keywords

BMC Public Health

ISSN: 1471-2458

Contact us